<SEC-DOCUMENT>0000886163-20-000112.txt : 20201030
<SEC-HEADER>0000886163-20-000112.hdr.sgml : 20201030
<ACCEPTANCE-DATETIME>20201030080330
ACCESSION NUMBER:		0000886163-20-000112
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20201030
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201030
DATE AS OF CHANGE:		20201030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		201274798

	BUSINESS ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lgnd-20201030.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:5304df3c-2700-420a-863a-c55b8768b11f,g:fa3fa23e-7c8d-4a08-b5c8-98ca24e07ddf,d:125df7aae54b4dce865239a515196ba9--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lgnd-20201030</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV80L2ZyYWc6MjE0MTc4NmQ5NTU3NGNmZjhjMGI0MGI0M2ZkNmU0MjAvdGFibGU6NWVjNmQwMTYxMTliNDEwZDkxYTM2M2QxMTk2YzVkZWEvdGFibGVyYW5nZTo1ZWM2ZDAxNjExOWI0MTBkOTFhMzYzZDExOTZjNWRlYV8yLTEtMS0xLTA_0ae55155-b815-484d-8d94-ca293c69179e">0000886163</ix:nonNumeric><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV80L2ZyYWc6MjE0MTc4NmQ5NTU3NGNmZjhjMGI0MGI0M2ZkNmU0MjAvdGFibGU6NWVjNmQwMTYxMTliNDEwZDkxYTM2M2QxMTk2YzVkZWEvdGFibGVyYW5nZTo1ZWM2ZDAxNjExOWI0MTBkOTFhMzYzZDExOTZjNWRlYV8zLTEtMS0xLTA_06a9caea-9156-4e7a-ae6d-905c3271aa15">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lgnd-20201030.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-30</xbrli:startDate><xbrli:endDate>2020-10-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i125df7aae54b4dce865239a515196ba9_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:173%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:173%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:173%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:173%">______________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:173%">FORM <ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF85Nw_1ce5cf2c-3c70-413c-a1ee-92f2160c4487">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:173%">______________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:173%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:173%">Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:173%">Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF8yNTI_24a11774-bb8f-485c-a8b7-62092810aa8f">October 30, 2020</ix:nonNumeric> </span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:173%"><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF8yNTY_ad6c1bba-57d5-4a6d-8553-e957e3fa3156">LIGAND PHARMACEUTICALS INC</ix:nonNumeric>ORPORATED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">     </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.538%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6NDIxYjY2OThlMTRjNDZiYmI1ZDA3MjYyZGQxZGYxZGQvdGFibGVyYW5nZTo0MjFiNjY5OGUxNGM0NmJiYjVkMDcyNjJkZDFkZjFkZF8wLTAtMS0xLTA_2fcffdfd-211e-4d46-920f-effcaa9bc47e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6NDIxYjY2OThlMTRjNDZiYmI1ZDA3MjYyZGQxZGYxZGQvdGFibGVyYW5nZTo0MjFiNjY5OGUxNGM0NmJiYjVkMDcyNjJkZDFkZjFkZF8wLTEtMS0xLTA_0a7a8761-51d4-4e7d-89a0-2989ce674eb9">001-33093</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6NDIxYjY2OThlMTRjNDZiYmI1ZDA3MjYyZGQxZGYxZGQvdGFibGVyYW5nZTo0MjFiNjY5OGUxNGM0NmJiYjVkMDcyNjJkZDFkZjFkZF8wLTItMS0xLTA_a99a64cc-e76c-4cd8-bc6c-3043be26da8e">77-0160744</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:2px 1.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Identification No.)</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6ZWQzNjYyNWQ1NmQ3NDQyNmI5NGVmNTg0MTA4ZWY1NDUvdGFibGVyYW5nZTplZDM2NjI1ZDU2ZDc0NDI2Yjk0ZWY1ODQxMDhlZjU0NV8wLTAtMS0xLTA_586e777e-1bad-414a-b12a-57a180b72279">3911 Sorrento Valley Boulevard, Suite 110</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6ZWQzNjYyNWQ1NmQ3NDQyNmI5NGVmNTg0MTA4ZWY1NDUvdGFibGVyYW5nZTplZDM2NjI1ZDU2ZDc0NDI2Yjk0ZWY1ODQxMDhlZjU0NV8xLTAtMS0xLTA_ce68e441-0689-452f-b102-de8653963307">San Diego</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6ZWQzNjYyNWQ1NmQ3NDQyNmI5NGVmNTg0MTA4ZWY1NDUvdGFibGVyYW5nZTplZDM2NjI1ZDU2ZDc0NDI2Yjk0ZWY1ODQxMDhlZjU0NV8yLTAtMS0xLTA_921cf68e-1f78-47ac-9b80-f88596a63822">CA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6ZWQzNjYyNWQ1NmQ3NDQyNmI5NGVmNTg0MTA4ZWY1NDUvdGFibGVyYW5nZTplZDM2NjI1ZDU2ZDc0NDI2Yjk0ZWY1ODQxMDhlZjU0NV8yLTItMS0xLTA_62bfa62e-9177-4fb8-a16c-1885fe12cc33">92121</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF8zMzQ_8423a1c8-95b7-448e-9fdd-38376299b632">858</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF8zMzg_05a2ae96-5e3e-4016-86f1-b7201f7bfd66">550-7500</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">N/A</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span><br/></span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF82MzU_a2af5cb6-6e56-45f0-a917-e9a3b9b373af">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF83MjQ_0db458eb-8250-4b05-813c-6b2fb298eb61">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF84MTQ_910c9bc4-7b7a-4e4a-9da6-c7c9b3aa050b">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF85MjA_99592698-f060-4958-ae1b-326f12d87e7b">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Ac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">t:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:37.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.610%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6ZGI5MTc2MmQ0ZjBmNGM5Zjg2OTQ1MTI0ZWY2N2Q2ZGMvdGFibGVyYW5nZTpkYjkxNzYyZDRmMGY0YzlmODY5NDUxMjRlZjY3ZDZkY18xLTAtMS0xLTA_7028af25-f3ca-49e7-9177-e41af13512e3">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6ZGI5MTc2MmQ0ZjBmNGM5Zjg2OTQ1MTI0ZWY2N2Q2ZGMvdGFibGVyYW5nZTpkYjkxNzYyZDRmMGY0YzlmODY5NDUxMjRlZjY3ZDZkY18xLTEtMS0xLTA_df6977e7-9d26-4c77-b323-d7748b25d850">LGND</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6ZGI5MTc2MmQ0ZjBmNGM5Zjg2OTQ1MTI0ZWY2N2Q2ZGMvdGFibGVyYW5nZTpkYjkxNzYyZDRmMGY0YzlmODY5NDUxMjRlZjY3ZDZkY18xLTItMS0xLTA_9e64cb86-1250-4668-925a-6932559fba61">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF8xMzU0_3e5516f7-906e-4e59-8c25-340a31dd95e3">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i125df7aae54b4dce865239a515196ba9_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">On October 30, 2020, Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221;) issued a press release announcing its financial results for the three- and nine- months ended September 30, 2020. A copy of this press release is furnished herewith as Exhibit 99.1 to this report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-bottom:19pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-right:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-right:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-right:3pt;text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q32020earningsreleasee.htm">99.1</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:-3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Press release dated October 30, 2020.</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:20pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:6pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.993%"><tr><td style="width:1.0%"></td><td style="width:40.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 2.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIGAND PHARMACEUTICALS INCORPORATED</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 2.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: October 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:38.25pt;padding-right:2.25pt;text-indent:-33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Charles S. Berkman         </span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:38.25pt;padding-right:2.25pt;text-indent:-33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:    Charles S. Berkman</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:38.25pt;padding-right:2.25pt;text-indent:-33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:    Senior Vice President, General Counsel and Secretary </span></div></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q32020earningsreleasee.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ifba0cec3c9464ce4bc88dc4a7d04c118_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font><br></font></div><div><img alt="image11.jpg" src="image11.jpg" style="height:69px;width:196px"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:7.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Contacts&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals Incorporated</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">LHA Investor Relations</font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Patrick O'Brien</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bruce Voss</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">investors&#64;ligand.com</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">bvoss&#64;lhai.com</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Phone&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(858) 550-7893</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Phone&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(310) 691-7100</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Twitter&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#64;Ligand_LGND</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:85%">Ligand Reports Third Quarter 2020 Financial Results</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:85%">Conference Call with Slides Begins at 8&#58;30 a.m. Eastern Time Today</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%">SAN DIEGO (October 30, 2020) &#8211; Ligand Pharmaceuticals Incorporated (NASDAQ&#58; LGND) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">today reported financial results for the three- and nine-months ending September 30, 2020 and provided an operating forecast and program updates.  Ligand management will host a conference call with slides today beginning at 8&#58;30 a.m. Eastern time to discuss this announcement and answer questions. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;Our business is performing very well across the board.  We are pleased to be reporting strong third quarter financial results and foresee substantial momentum and accelerating growth as we close out 2020 and move into 2021,&#8221; said John Higgins, Chief Executive Officer of Ligand.  &#8220;Revenue is tracking well against the guidance we raised throughout the year, and we are pleased with our earnings performance with adjusted diluted EPS coming in much higher than our outlook at the start of 2020.&#8221;  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Higgins continued, &#8220;Beyond robust financial performance, we closed three acquisitions in the past three months, with Pfenex in particular providing significant P&#38;L contribution and a major new technology platform backed by top-tier partnering contracts.  We are proud of our contribution to helping make Gilead's Veklury possible as the first and only FDA approved treatment for COVID-19.  Our core business is very strong and forms the foundation of Ligand&#8217;s value, but we certainly see the surge in Captisol business due to Veklury as meaningful upside now and over the next few quarters.  Captisol material sales will provide Ligand increased cash flow and, in turn, the opportunity to invest in other areas to drive future growth.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Third Quarter 2020 Financial Results</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Total revenues for the third quarter of 2020 were $41.8 million, compared with $24.8 million for the same period in 2019.  Royalties for the third quarter of 2020 were $9.0 million, compared with $9.8 million for the same period in 2019. Royalties for the third quarter of 2020 and 2019 primarily consisted of royalties from Kyprolis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and EVOMELA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Captisol sales were $23.4 million for the third quarter of 2020, compared with $6.8 million for the same period in 2019, primarily reflecting higher sales of Captisol for use with remdesivir.  Contract revenue was $9.5 million for the third quarter of 2020, compared with $8.2 million for the same period in 2019.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cost of goods sold was $6.4 million for the third quarter of 2020, compared with $3.1 million for the same period in 2019, with the increase primarily attributable to higher sales of Captisol.  Amortization of intangibles was $3.9 million for the third quarter of 2020, compared with $3.6 million for the same period </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in 2019, with the increase attributable to the Icagen acquisition in April 2020.  Research and development expense was $12.9 million for the third quarter of 2020, compared with $13.7 million for the same period of 2019, with the decrease primarily attributable to amortization of research and development expense related to Novan and Palvella in the prior-year period.  General and administrative expense was $15.0 million for the third quarter of 2020, compared with $9.5 million for the same period in 2019, with the increase primarily attributable to additional expenses from Icagen and other acquisition-related costs. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Net loss for the third quarter of 2020 was $6.7 million, or $0.42 per share, compared with net loss of $15.3 million, or $0.81 per share, for the same period in 2019.  Net loss for the third quarter of 2020 included a $11.7 million net non-cash loss from the value of Ligand&#8217;s short-term investments, while net loss for the third quarter of 2019 included a $13.4 million net non-cash loss from the value of Ligand&#8217;s short-term investments.  Adjusted net income for the third quarter of 2020 was $17.5 million, or $1.04 per diluted share, compared with $9.5 million, or $0.49 per diluted share, for the same period in 2019.  Please see the table below for a reconciliation of net income&#47;(loss) to adjusted net income.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">As of September 30, 2020, Ligand had cash, cash equivalents and short-term investments of $795 million.  Following the closing of the Pfenex acquisition on October 1, Ligand had approximately $400 million in cash, cash equivalents and short-term investments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Year-to-Date Financial Results</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Total revenues for the nine months ended September 30, 2020 were $116.4 million, compared with $93.3 million for the same period in 2019.  Royalties for the nine months ended September 30, 2020 were $22.8 million  and primarily consisted of royalties from Kyprolis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and EVOMELA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Royalties for the nine months ended September 30, 2019 were $35.9 million and included $14.2 million in royalties from Promacta&#59; Ligand sold its Promacta license to Royalty Pharma as of March 6, 2019.  Captisol sales were $69.0 million for the nine months ended September 30, 2020, compared with $24.4 million for the same period in 2019, with the increase primarily reflecting higher sales of Captisol for use with remdesivir.  Contract revenue was $24.7 million for the nine months ended September 30, 2020, compared with $33.0 million for the same period in 2019, with the change due to the timing of partner events.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cost of goods sold was $18.7 million for the nine months ended September 30, 2020, compared with $9.4 million for the same period in 2019, with the increase primarily attributable to higher sales of Captisol.  Amortization of intangibles for the nine months ended September 30, 2020 was $11.3 million, compared with $10.6 million for the same period in 2019, with the increase attributable to the Icagen acquisition.  Research and development expense was $37.5 million for the nine months ended September 30, 2020, compared with $37.2 million for the same period of 2019.  General and administrative expense was $34.4 million for the nine months ended September 30, 2020, compared with $31.6 million for the same period in 2019, with the  increase primarily attributable to additional expenses from Icagen and other acquisition-related costs.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Net loss for the nine months ended September 30, 2020 was $8.7 million, or $0.54 per share, compared with net income of $636.7 million, or $31.29 per diluted share, for the same period in 2019.  Net loss for the nine months ended September 30, 2020 included a net non-cash loss in the value of Ligand&#8217;s short-term investments of $17.9 million, while net income for the same period in 2019 was impacted by an after-tax gain of approximately $643 million on the sale of the Promacta license.  Adjusted net income for the nine months ended September 30, 2020 was $49.4 million, or $2.93 per diluted share, compared with $48.2 million, or $2.37 per diluted share, for the same period in 2019.  Please see the table below for a reconciliation of net income&#47;(loss) to adjusted net income.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%">2020 and 2021 Financial Guidance </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">Ligand reiterates 2020 financial guidance and 2021 financial guidance newly introduced at its Analyst Day event on October 20, 2020, as follows&#58;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%;padding-left:13.8pt">For 2020, Ligand expects total revenue to be approximately $170 million and adjusted diluted EPS to be $3.95.  Total revenue is expected to consist of $92 million in Captisol sales, $33 million in royalty revenue and $45 million in contract revenue.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%;padding-left:13.8pt">For 2021, Ligand expects total revenue to be approximately $285 million and adjusted diluted EPS to be $6.00.  Total revenue is expected to consist of $200 million of Captisol sales, $45 million in royalty revenue and $40 million in contract revenue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:99%">Third Quarter 2020 and Recent Business Highlights </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:99%">OmniAb</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:99%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:99%"> Platform Updates</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:95%">OmniAb is Ligand&#8217;s multi-species antibody platform for the discovery of mono- and bi-specific therapeutic human antibodies.  As of the third quarter of 2020, more than 8,500 clinical subjects have been or are planned to be treated by partners in clinical trials with OmniAb-derived antibodies. New clinical programs are pending at Johnson &#38; Johnson and Merck, among others.  Ligand expects the first regulatory submission for OmniAb-derived antibodies in 2021, with potential for as many as 10 approvals expected by 2025.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:95%">As part of the OmniAb platform, Ligand recently announced OmniTaur&#8482;, featuring Ultralong CDR-H3 humanized binding domains recently acquired from Taurus Biosciences.  The OmniAb platform also includes the ultra-high resolution, high-speed automated antibody selection technology acquired from xCella Biosciences.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:95%">Multiple OmniAb partners reported clinical or regulatory progression with OmniAb-derived antibodies during the third quarter.  Additionally, three Ligand partners (Takeda, Immunoprecise and Genovac) are pursuing development of therapeutic antibodies for the treatment of COVID-19 that were discovered with OmniAb.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:95%">CStone Pharmaceuticals announced the formation of a $480 million strategic collaboration that encompasses a $200 million equity investment by Pfizer Hong Kong in CStone, collaboration between CStone and Pfizer Investment for the development and commercialization of CStone&#8217;s PD-L1 antibody sugemalimab (CS1001) in mainland China and a framework between CStone and Pfizer Investment to bring additional oncology assets to the Greater China market.  CStone announced updated results from two clinical studies of sugemalimab at the 2020 Chinese Society of Clinical Oncology Annual Meeting.  CStone announced that sugemalimab met the primary endpoint as first-line treatment in stage IV squamous and non-squamous non-small cell lung cancer.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:95%">Immunovant announced positive topline results from a multicenter, placebo-controlled Phase 2a trial (ASCEND MG) of IMVT-1401, a novel investigational anti-FcRn antibody delivered by subcutaneous injection, in patients with myasthenia gravis (MG).  A registration-enabling Phase 3 MG trial is expected to initiate in the first half of 2021.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:99%">Captisol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:99%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:99%"> Business Updates </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">To date in 2020, Ligand has entered into more than 120 Captisol research use agreements and eight clinical and&#47;or commercial license agreements.  This is the highest number of use agreements to be signed in a single year since the invention of Captisol.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Captisol is utilized in the formulation of Gilead Sciences&#8217; Veklury</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (remdesivir), which on October 22, 2020 received U.S. Food and Drug Administration (FDA) approval for the treatment of patients with COVID-19 requiring hospitalization.  The product has regulatory approvals for the treatment of moderate or severe COVID-19 in over 50 countries and is included in more than 30 ongoing clinical trials.  Ligand is supplying Captisol to Gilead under a recently signed 10-year supply agreement.  Ligand is also </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">supplying Captisol to Gilead&#8217;s voluntary licensing generic partners who are manufacturing remdesivir for 127 low- and middle-income countries.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Partner Marinus was recently awarded a BARDA contract by the U.S. government to develop Captisol-enabled IV ganaxolone for the treatment of refractory status epilepticus (RSE) caused by nerve agent exposure.  Marinus also announced it had satisfied the FDA protocol-specific questions for the registrational Phase 3 trial (the RAISE trial) in RSE, allowing the company to begin patient enrollment in October.  Topline data are anticipated in the first half of 2022. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:95%">Ligand plans to initiate a potentially pivotal trial for Captisol-enabled Iohexol (CE-Iohexol) in December 2020.  CE-Iohexol is an iodine-based contrast agent for hospital-based imaging procedures. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:99%">Protein Expression Technology Platform Updates</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:99%">On October 1, Ligand closed the previously announced acquisition of Pfenex, Inc.  Pfenex brings to Ligand a proprietary protein expression technology, as well as major collaborations with Jazz Pharmaceuticals, Merck, Serum Institute of India and Alvogen, each of which has potential to contribute meaningfully to Ligand&#8217;s royalty revenue.  Our partner Merck announced positive data from two Phase 3 studies with V114, which uses the protein expression technology, evaluating the safety, tolerability and immunogenicity of the investigational 15-valent pneumococcal conjugate vaccine with plans for global regulatory licensure applications in the fourth quarter 2020.  Also using the platform, Jazz Pharmaceutical&#8217;s Erwinaze supply challenges due to issues with their manufacturer were solved, resulting in a robust process showing manufacturing consistency and efficiency.  The program was completed from commencement to projected first BLA filing in approximately four years.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:99%">Ligand entered into a new 10-year CRM197 supply agreement with a global multi-national pharmaceutical partner focused on vaccine development.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:99%">Other Business Updates</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Ligand announced the sale of its Vernalis research operations and internal programs to HitGen Inc. for $25 million in cash.  Under the terms of the agreement, Ligand will retain economic rights on completed collaboration licenses as well as a share of the economic rights on current research collaboration contracts. The transaction is expected to close in the fourth quarter of 2020, subject to customary closing conditions.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Several partners also had significant regulatory, financing and business updates during the third quarter&#58;  Verona Pharma announced initiation of its ENHANCE Phase 3 trials, Retrophin announced enrollment of the first 280 patients in the pivotal Phase 3 PROTECT study of sparsentan in IgA nephropathy, and Sermonix Pharmaceuticals announced a collaboration with Eli Lilly to study lasofoxifene in combination with Lilly&#8217;s CDK 4 and 6 inhibitor abemaciclib in metastatic breast cancer.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">Ligand provides regular updates on individual partner events through its Twitter account, &#64;Ligand_LGND.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%">Adjusted Financial Measures</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">The Company reports adjusted net income and adjusted net income per diluted share in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.  The Company&#8217;s financial measures under GAAP include share-based compensation expense, amortization of debt-related costs, amortization related to acquisitions and intangible assets, changes in contingent liabilities, mark-to-market adjustments for amounts relating to its equity investments in public companies, excess tax benefit from share-based compensation, gain on the sale of Promacta and others that are listed in the itemized reconciliations between GAAP and adjusted financial measures included at the end of this press release.  However, other than with respect to total revenues, the Company only provides financial guidance on an adjusted basis and does not provide reconciliations of such forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in contingent </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">liabilities, changes in the market value of its investments in public companies, stock-based compensation expense and effects of any discrete income tax items.  Management has excluded the effects of these items in its adjusted measures to assist investors in analyzing and assessing the Company&#8217;s past and future core operating performance.  Additionally, adjusted earnings per diluted share is a key component of the financial metrics utilized by the Company&#8217;s board of directors to measure, in part, management&#8217;s performance and determine significant elements of management&#8217;s compensation.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%">Conference Call</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">Ligand management will host a conference call with slides today beginning at 8&#58;30 a.m. Eastern time (5&#58;30 a.m. Pacific time) to discuss this announcement and answer questions.  To participate via telephone, please dial (833) 325-0071 from the U.S. or (720) 405-1612 from outside the U.S., using the conference ID 9279386.  To participate via live or replay webcast, a link is available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">www.ligand.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">. Slides to accompany the conference call are available </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">here</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">About OmniAb</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">OmniAb is a multi-species transgenic-animal platform consisting of six different technologies used for producing mono- and bispecific human therapeutic antibodies. OmniRat</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> animals comprise the industry&#8217;s first human monoclonal antibody technology based on rats. Because they have a complete immune system with a diverse antibody repertoire, OmniRat animals generate antibodies with human idiotypes as effectively as wild-type animals make rat antibodies. OmniMouse</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> is a transgenic mouse that complements OmniRat and expands epitope coverage. OmniFlic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> is an engineered rat with a fixed light chain for development of bispecific, fully human antibodies. OmniChicken animals comprise the industry&#8217;s first human monoclonal antibody technology based on chickens. The OmniClic chicken is specifically developed to facilitate the generation of bispecific antibodies and retains the ability to generate diverse, high quality affinity matured antibodies. All five types of OmniAb therapeutic human antibody platform, OmniRat, OmniFlic, OmniMouse, OmniChicken</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, OmniClic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">OmniTaur&#8482;,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> use patented technology, have broad freedom to operate, produce highly diversified, fully human antibody repertoires optimized in vivo for immunogenicity, manufacturability, and therapeutic efficacy, and deliver fully human antibodies with high affinity, specificity, expression, solubility and stability - Naturally Optimized Human Antibodies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">About Captisol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.  Captisol was invented and initially developed by scientists in the laboratories of Dr. Valentino Stella, University Distinguished Professor at the University of Kansas&#8217; Higuchi Biosciences Center for specific use in drug development and formulation.  This unique technology has enabled several FDA-approved products, including Gilead&#8217;s </font><font style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">VEKLURY</font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Amgen&#8217;s KYPROLIS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, Baxter International&#8217;s NEXTERONE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, Acrotech Biopharma L.L.C.&#8217;s and CASI Pharmaceuticals&#8217; EVOMELA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, Melinta Therapeutics&#8217; BAXDELA&#8482; and Sage Therapeutics&#8217; ZULRESSO&#8482;. There are many Captisol-enabled products currently in various stages of development.  Ligand maintains a broad global patent portfolio for Captisol with more than 400 issued patents worldwide relating to the technology (including 37 in the U.S.) and with the latest expiration date in 2033.  Other patent applications covering methods of making Captisol, if issued, extend to 2040.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Protein Expression Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> Platform </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Protein Expression Technology is a robust, validated, cost-effective and scalable platform for recombinant protein production, and is especially well-suited for complex, large-scale protein production where traditional systems are not suitable.  Multiple global manufacturers have demonstrated consistent success with the platform and the technology is currently out-licensed for numerous commercial and development-stage programs.  The versatility of the platform has been demonstrated in the production of enzymes, peptides, antibody derivatives and engineered non-natural proteins.  Partners seek the platform as it can contribute significant value to biopharmaceutical development programs by reducing </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">development timelines and costs for manufacturing therapeutics and vaccines.  Given pharmaceutical industry trends toward large molecules with increasing structural complexities, the Protein Expression Technology is well positioned to meet these growing needs as the most comprehensive broadly available protein production platform in the industry.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%">About Ligand Pharmaceuticals</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.  Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure.  Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company.  Our business model is based on doing what we do best&#58; drug discovery, early-stage drug development, product reformulation and partnering.  We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.  Ligand&#8217;s OmniAb</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> technology platform is a patent-protected transgenic animal platform used in</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">the discovery of fully human mono- and bispecific therapeutic antibodies.  The Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.  Ligand&#8217;s Protein Expression Technology is a robust, validated, cost-effective and scalable platform for recombinant protein production, and is especially well-suited for complex, large-scale protein production where traditional systems are not suitable.  Ab Initio&#8482; technology and services for the design and preparation of customized antigens enable the successful discovery of therapeutic antibodies against difficult-to-access cellular targets.  Ligand has established multiple alliances, licenses and other business relationships with the world&#8217;s leading pharmaceutical companies including Amgen, Merck, Pfizer, Sanofi, Janssen, Takeda, Servier, Gilead Sciences and Baxter International.  For more information, please visit www.ligand.com. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%">Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release.  Words such as &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; and &#8220;will,&#8221; and similar expressions, are intended to identify forward-looking statements.  These forward-looking statements include, without limitation, statements regarding&#58; the number of patients that may be treated in clinical partners of drug candidates based on OmniAb&#59; Ligand&#8217;s ability to supply Captisol to Gilead and other partners,&#59; the potential opportunities for Ligand and its partners related to development of COVID-19 treatments&#59; whether the planned clinical trial of CE-Iohexol can serve as a basis for registration with the FDA&#59; the timing of product launches by Ligand or its partners&#59; guidance regarding the full-year 2020 and 2021 financial results&#59; and the expected timing and completion of the transaction with HitGen.  Actual events or results may differ from Ligand's expectations due to risks and uncertainties inherent in Ligand&#8217;s business, including, without limitation&#58; Ligand may not receive expected revenue from royalties, Captisol sales, contract and service revenue&#59; the COVID-19 pandemic has disrupted Ligand&#8217;s and its partners&#8217; business, including delaying manufacturing, preclinical studies and clinical trials and product sales, and impairing global economic activity, all of which could materially and adversely impact Ligand&#8217;s results of operations and financial condition&#59; Ligand may not achieve its guidance for 2020 or 2021&#59; the FDA may revise or revoke approval for remdesivir for the treatment of patients with COVID-19 requiring hospitalization based on later information regarding the safety or efficacy of remdesivir&#59; alternative COVID-19 therapies or vaccines may be approved or the risk of coronavirus infection could significantly diminish, any of which could materially and adversely affect the commercial opportunity for remdesivir&#59; there may not be a market for the product(s) even if successfully developed and approved&#59;  Ligand may be unable to scale-up the supply of Captisol or at acceptable prices&#59; Ligand is currently dependent on single source sole supplier for Captisol and failures by such supplier may result in delays or inability to meet the Captisol demands of its partners&#59; Amgen, Acrotech Biopharma or other Ligand partners, may not execute on their sales and marketing plans for marketed products for which Ligand has an economic interest&#59; Ligand or its partners may not be able to protect their intellectual property and patents covering certain products and technologies may be challenged or invalidated&#59; Ligand's partners may terminate any of its agreements or development or commercialization of any of its products&#59; Ligand may not generate expected revenues under its existing license agreements and may experience significant costs as the result of potential delays under its supply agreements&#59; Ligand and its </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">partners may experience delays in the commencement, enrollment, completion or analysis of clinical testing for its product candidates, or significant issues regarding the adequacy of its clinical trial designs or the execution of its clinical trials, which could result in increased costs and delays, or limit Ligand's ability to obtain regulatory approval&#59; unexpected adverse side effects or inadequate therapeutic efficacy of Ligand's product(s) could delay or prevent regulatory approval or commercialization&#59; challenges, costs and charges associated with integrating recently completed acquisitions with Ligand&#8217;s existing businesses&#59; risks associated with closing the HitGen transaction and the timing thereof&#59; and ongoing or future litigation could expose Ligand to significant liabilities and have a material adverse effect on the company.  The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price.  Additional information concerning these and other risk factors affecting Ligand can be found in prior press releases available at www.ligand.com as well as in Ligand's public periodic filings with the Securities and Exchange Commission available at www.sec.gov.  Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release, including the possibility of additional contract revenue we may receive.  This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%">Other Disclaimers and Trademarks</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">The information in this press release regarding certain third-party products and programs, including Kyprolis, an Amgen product and EVOMELA, an Acrotech Biopharma product, comes from information publicly released by the owners of such products and programs.  Ligand is not responsible for, and has no role in, the development of such products or programs.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">Ligand owns or has rights to trademarks and copyrights that it uses in connection with the operation of its business including its corporate name, logos and websites. Other trademarks and copyrights appearing in this press release are the property of their respective owners.  The trademarks Ligand owns include Ligand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">, Captisol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">and OmniAb</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">. Solely for convenience, some of the trademarks and copyrights referred to in this press release are listed without the &#174;, &#169; and &#8482; symbols, but Ligand will assert, to the fullest extent under applicable law, its rights to its trademarks and copyrights.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Tables Follow&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited, in thousands, except per share amounts)</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:35.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #333333;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #333333;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #333333;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #333333;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #333333;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues&#58;</font></div></td><td colspan="3" style="border-top:1pt solid #333333;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #333333;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #333333;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #333333;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,005&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,767&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,751&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,931&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Captisol</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,389&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,849&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,966&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,357&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,454&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,192&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,712&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,991&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt;padding-right:-24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</font></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,848&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,808&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116,429&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,279&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating costs and expenses&#58;</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of Captisol</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,353&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,147&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,680&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,410&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangibles</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,875&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,552&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,285&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,560&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,853&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,742&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,476&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,244&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,020&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,525&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,353&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,607&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-48pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating costs and expenses</font></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,101&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,966&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,794&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,821&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from sale of Promacta license</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">812,797&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,747&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,158)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,635&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">817,255&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from short-term investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,862)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,297)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,143)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,524)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,278)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,597)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,340)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,321)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(219)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,940&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total other income (loss), net</font></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,359)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,713)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28,543)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,441)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income (loss) before income taxes</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,612)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,871)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,908)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,814&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,911&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,620&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(168,147)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income (loss)&#58;</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,701)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,251)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,746)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">636,667&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net income (loss) per share</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.42)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.81)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.54)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.51&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares used in basic per share calculation</font></div></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,082&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,770&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,222&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,586&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net income (loss) per share</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.42)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.81)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.54)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.29&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares used in diluted per share calculations</font></div></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,082&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,770&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,222&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,349&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) Certain reclassifications have been made to the prior period data to conform with the current period presentation.</font></div><div style="text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited, in thousands)</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.081%"><tr><td style="width:1.0%"></td><td style="width:59.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="border-top:2pt solid #333333;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #333333;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-84pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Cash, cash equivalents and short-term investments</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">795,070&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,069,867&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-96pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Accounts receivable, net</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,907&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,387&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-120pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Inventory</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,430&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,296&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-132pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Income taxes receivable</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,361&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Other current assets</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,191&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,734&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Assets held for sale</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,143&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-96pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</font></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">857,741&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,123,645&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Deferred income taxes, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,026&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,608&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Goodwill and other identifiable intangible assets, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326,718&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305,677&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Commercial license and other economic rights, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,834&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,090&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Other assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,130&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,895&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-120pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</font></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,247,449&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494,915&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</font></div></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-156pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Accounts payable and accrued liabilities</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,667&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,256&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-168pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Current contingent liabilities</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,194&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,607&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Deferred revenue</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,404&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,139&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Income taxes payable</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">674&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Liabilities related to assets held for sale</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,361&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities</font></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,300&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,002&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-204pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 convertible senior notes, net</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">454,973&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638,959&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contingent liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,604&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,335&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,508&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,937&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,240&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,450&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-168pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</font></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549,625&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">727,683&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders' equity</font></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">697,824&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767,232&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-192pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities and stockholders' equity</font></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,247,449&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494,915&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADJUSTED FINANCIAL MEASURES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited, in thousands, except per share amounts)</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:44.702%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #333333;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #333333;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #333333;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (6)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #333333;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #333333;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #333333;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</font></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,701)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,251)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,746)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">636,667&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,741&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,297&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,753&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,215&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,301&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,560&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,743&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,562&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization related to acquisitions and intangible assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,875&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,552&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,285&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,560&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of commercial license and other economic rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(228)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,595&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,277&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,048&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in contingent liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(222)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(384)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">772&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition and integrations costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,956&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,956&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from short-term investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,862&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,297&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,143&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,524&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gain from short-term investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,811&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">761&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">687&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,070&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(718)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect of adjusted reconciling items above</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,610)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,200)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,315)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,342)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Excess tax benefit from share-based compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(172)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,113)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,371)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,494&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,894&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,430&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">690,776&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from sale of Promacta license, net of tax</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,350)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(642,615)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted net income</font></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,494&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,544&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,430&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,161&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted per-share amounts attributable to common shareholders&#58;</font></div></td><td colspan="3" style="border-top:3pt double #333333;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #333333;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #333333;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #333333;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.42)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.81)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.54)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.29&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.48&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.34&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.90&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.40&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.09&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization related to acquisitions and intangible assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.70&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.52&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of commercial license and other economic rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.20&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.49&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in contingent liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.02)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.04&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition and integrations costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.31&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.31&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from short-term investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.61&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.70&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.06&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.42&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gain from short-term investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.05&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.04&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.04)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect of adjusted reconciling items above</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.59)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.44)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.08)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.75)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Excess tax benefit from share-based compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.07)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.07)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustment for shares excluded due to anti-dilution effect on GAAP net loss</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.02)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.12)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.04&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.61&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.93&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.95&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from sale of Promacta license, net of tax</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.12)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.58)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted net income</font></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.04&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.49&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.93&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.37&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP - Weighted average number of common shares-diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,082&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,770&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,222&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,349&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Add&#58; Shares excluded due to anti-dilutive effect on GAAP net loss</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">695&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">651&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted weighted average number of common shares-diluted</font></div></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,785&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,465&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,873&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,349&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Amounts represent non-cash debt related costs that are calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) For the three months ended September&#160;30, 2020, the amount represents the amortization of commercial license and other economic rights to revenue. For the three months ended September&#160;30, 2019, the amounts represent the amortization of commercial license and other economic rights to revenue and research and development expenses in the amounts of $(170) and $4,765, respectively. For the nine months ended September&#160;30, 2020, the amounts represent the amortization of commercial license and other economic rights to revenue and research and development expenses in the amount of $769 and $2,508, respectively.  For the nine months ended September&#160;30, 2019, the amounts represent the amortization of commercial license and other economic rights to revenue and research and development expenses in the amount of $913 and $9,135, respectively.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Amounts represent changes in fair value of contingent consideration related to Icagen, Crystal, CyDex, and Metabasis transactions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Amounts represent acquisition and integration related costs primarily in connection with the announced Pfenex acquisition.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5) Excess tax benefits from share-based compensation are recorded as a discrete item within the provision for income taxes on the consolidated statement of operations as a result of the adoption of an accounting pronouncement (ASU 2016-09) on January 1, 2017. Prior to the adoption, the amount was recognized in additional paid-in capital on the consolidated statement of stockholders' equity.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6) Certain reclassifications have been made to the prior period data to conform with the current period presentation.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADJUSTED FINANCIAL MEASURES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited, in thousands, except per share amounts)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:75.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2019</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,279&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; royalty revenue from Promacta</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,193)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted consolidated revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,086&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net income</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,161&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; royalty revenue from Promacta</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,193)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add&#58; tax effect of the royalty revenue from Promacta</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net income excluding royalty revenue from Promacta</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,016&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net income per diluted shares, excluding royalty revenue from Promacta</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.82&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP - weighted average number of common shares - diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,349&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"># # #</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lgnd-20201030.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:5304df3c-2700-420a-863a-c55b8768b11f,g:fa3fa23e-7c8d-4a08-b5c8-98ca24e07ddf-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lgnd="http://www.ligand.com/20201030" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ligand.com/20201030">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20201030_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20201030_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20201030_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20201030_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.ligand.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>lgnd-20201030_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:5304df3c-2700-420a-863a-c55b8768b11f,g:fa3fa23e-7c8d-4a08-b5c8-98ca24e07ddf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ligand.com/role/CoverPage" xlink:type="simple" xlink:href="lgnd-20201030.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CoverPage" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>lgnd-20201030_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:5304df3c-2700-420a-863a-c55b8768b11f,g:fa3fa23e-7c8d-4a08-b5c8-98ca24e07ddf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CoverPage" xlink:type="simple" xlink:href="lgnd-20201030.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CoverPage" xlink:type="extended" id="ia246d6361acd4d80810a20fb60f6e79e_CoverPage"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>lgnd-20201030_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:5304df3c-2700-420a-863a-c55b8768b11f,g:fa3fa23e-7c8d-4a08-b5c8-98ca24e07ddf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_b6fc363e-6260-4cfb-8984-3d99a3a9ddd1_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_c3468fcd-8335-4f0a-a759-17f4022a0022_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d8c0684f-be31-49e7-a42a-e6d9c9408388_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b7fd3f03-5c96-49d3-9a74-50fc03fd1832_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_3d976338-0444-4462-8570-624ceb1f0f37_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_302cd10e-e0a8-4928-af1f-911f7c02cccb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a9568f32-74cc-4ca8-b306-d14789f47ce2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f7039a89-5be7-43ca-a678-0555564dd6e5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_9bf977b1-f179-4468-b59f-db06332cb7ea_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2075e3a9-d528-4c81-95eb-5e2e7cb52c99_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ca1dab8c-8d2b-41b4-a0dc-65323f7ff323_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_45860afc-79cd-4c26-8052-c181d90ebfa5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a3192a8d-80cf-436b-b860-a78991a6a87f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c4b6fae9-c6ed-4a18-880e-3ab546bb4497_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_dac09759-d76e-459a-842c-50950024949c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0a17892d-a5ef-4237-be4d-e35dc834431c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_db6ad963-db39-4409-af1a-aa347de084d0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9ec6b2a7-bf8a-4be7-87b0-df61faca8020_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8979f22d-f52d-4dc4-84df-515bd57259f1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4ffe2d8c-c890-40d9-b62d-8404a34bea2c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_64ce5ab6-2c19-4f50-a140-ad2b06f41159_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ab2791f4-6755-44ed-b58b-d5c9f4f68c10_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_700804f8-0f14-4846-b76f-66a1b045c542_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>lgnd-20201030_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:5304df3c-2700-420a-863a-c55b8768b11f,g:fa3fa23e-7c8d-4a08-b5c8-98ca24e07ddf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ligand.com/role/CoverPage" xlink:type="simple" xlink:href="lgnd-20201030.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8d354ed6-56ab-4bbf-aa9f-fbb079f147f7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_EntityCentralIndexKey_8d354ed6-56ab-4bbf-aa9f-fbb079f147f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_666b8107-7c82-428a-9da4-17caa721576c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_AmendmentFlag_666b8107-7c82-428a-9da4-17caa721576c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_04138613-db2b-44b4-a608-0e8cbadb8cbc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_DocumentType_04138613-db2b-44b4-a608-0e8cbadb8cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f11f4f32-dfc9-41d1-b328-6a26a0ccc9ad" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_DocumentPeriodEndDate_f11f4f32-dfc9-41d1-b328-6a26a0ccc9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e48f72b0-db00-4d4d-a02a-850264acca3b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_EntityRegistrantName_e48f72b0-db00-4d4d-a02a-850264acca3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d3cf0bd4-e90b-4b5f-b99e-d6947f1f2e63" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d3cf0bd4-e90b-4b5f-b99e-d6947f1f2e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a7e31813-7271-4ed2-bcfb-355a39e5ac7f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_EntityFileNumber_a7e31813-7271-4ed2-bcfb-355a39e5ac7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3ad16c0d-5f83-4f55-afba-e6b6bbc389ad" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_EntityTaxIdentificationNumber_3ad16c0d-5f83-4f55-afba-e6b6bbc389ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c455fbfd-623d-4b9b-8487-858ee6038edf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_EntityAddressAddressLine1_c455fbfd-623d-4b9b-8487-858ee6038edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d98cf5cd-c756-4258-a84f-5955198001ae" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_EntityAddressCityOrTown_d98cf5cd-c756-4258-a84f-5955198001ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_04b99d7d-d516-45fb-8c8d-a00251259a91" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_EntityAddressStateOrProvince_04b99d7d-d516-45fb-8c8d-a00251259a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_49806208-8a64-47a1-99ce-f844fc4fbb6b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_EntityAddressPostalZipCode_49806208-8a64-47a1-99ce-f844fc4fbb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a01650c9-869a-48ac-9e2c-68ba84482091" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_CityAreaCode_a01650c9-869a-48ac-9e2c-68ba84482091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ff58c0b2-7c7a-4916-a46d-738e1047e648" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_LocalPhoneNumber_ff58c0b2-7c7a-4916-a46d-738e1047e648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_0ec1c8a9-a839-4a03-aa00-4abda75be5ce" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_WrittenCommunications_0ec1c8a9-a839-4a03-aa00-4abda75be5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_f6602d62-4aad-478c-83c8-4be64bd6a729" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_SolicitingMaterial_f6602d62-4aad-478c-83c8-4be64bd6a729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_04cf327c-dd9b-443d-bb8c-355bcce1eef9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_PreCommencementTenderOffer_04cf327c-dd9b-443d-bb8c-355bcce1eef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_01fd8ab2-c4b5-4f31-8be8-83c41bee1b06" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_01fd8ab2-c4b5-4f31-8be8-83c41bee1b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0b7f08b5-1056-43d6-9d9b-28260df83e98" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_Security12bTitle_0b7f08b5-1056-43d6-9d9b-28260df83e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_911ccbea-c7c3-4fb8-adc4-120a5b209b5d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_TradingSymbol_911ccbea-c7c3-4fb8-adc4-120a5b209b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_28ea76bf-c191-458b-9908-4e4f7f77ba3a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_SecurityExchangeName_28ea76bf-c191-458b-9908-4e4f7f77ba3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b4ca8f7d-0682-41c5-99b7-e79b137611ec" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87023f7d-259e-4d15-9879-e4dff74a5cd2" xlink:to="loc_dei_EntityEmergingGrowthCompany_b4ca8f7d-0682-41c5-99b7-e79b137611ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image11.jpg
<TEXT>
begin 644 image11.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !   N(U$2  0    !   N(P
M  !!9&]B92!);6%G95)E861Y  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (+!<8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%;-AXZ\/W_EK]M^SROGY+A2FW&>K?='3U_7B@#HZ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7SC7T=7SC0 4444P"BBB@ KVOP%_P B7I__ &T_]&-7BE>U^ O^
M1+T__MI_Z,:@#HZ***0!1110 4444 %%%% !1110 4444 %%%% 'SC1113 *
M*** "BBB@#T?X4_\Q?\ [8_^SUZ/7G'PI_YB_P#VQ_\ 9Z]'I %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !6=KM^=-T.\NU+!TCPA4 X8\*<'W(K1KE_'TTD7AU
M41L++.J.,=1@MC\U'Y5AB9N%&4EV-\-!5*T8OJSS&BBBOD#[,**** "BBB@
MKVO2[S^T-*M;LE"TL2LVP\!L<C\#D?A7BE>L^#?^13LO^VG_ *&U>ME$FJLH
M^7]?F>/G,4Z49=G^?_#&[1117T!\Z%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5\XU]'5\XT %%%%, HHHH *]K\!?\B7I_P#V
MT_\ 1C5XI7M?@+_D2]/_ .VG_HQJ .CHHHI %%%% !1110 4444 %%%% !11
M10 4444 ?.-%%%, HHHH **** /1_A3_ ,Q?_MC_ .SUZ/7G'PI_YB__ &Q_
M]GKT>D 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *^<:^CJ^<: "BBBF 4444 %>U^ O^
M1+T__MI_Z,:O%*]K\!?\B7I__;3_ -&-0!T=%%%( HHHH **** "BBB@ HHH
MH **** "BBB@#YQHHHI@%%%% !1110!Z/\*?^8O_ -L?_9Z]'KSCX4_\Q?\
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M4Y# ]"#W%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHK-_X2'1?^@QI_\ X$I_C0!I45SG_">^
M&O\ H)?^0)/_ (FC_A/?#7_02_\ ($G_ ,30!T=%9<?B30Y8DD75[$*ZA@&G
M53@^H)R#[&KMK>6M]$9;2YAN(PVTM%(' /ID=^10!/1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 454NM5TZQ
ME$5W?VMO(5W!99E0D>N">G!JE=>*] LXA)+JUJREMN(G\TY^BY...M &Q17.
M?\)[X:_Z"7_D"3_XFG1^.?#<LJ1KJ:AG8*"T3J,GU)7 'N: .AHK-_X2'1?^
M@QI__@2G^-:5 !1110 4444 %%%% !7SC7T=7SC0 4444P"BBB@ KVOP%_R)
M>G_]M/\ T8U>*5[7X"_Y$O3_ /MI_P"C&H Z.BBBD 4444 %%%% !1110 44
M44 %%%% !1110!\XT444P"BBB@ HHHH ]'^%/_,7_P"V/_L]>CUYQ\*?^8O_
M -L?_9Z]'I %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!RNO>/=,T:62VB#7EVC;6CC.U4(QD,WKR>@/(P<5R<GQ0U<RN8K
M.Q6,L=JLKL0.P)W#)]\"N+N+B6[N9;B9MTLKEW; &6)R3@>]1TP.HN/B#XCF
MG:2.[C@4XQ''"I4<=MP)_6H_^$]\2_\ 02_\@1__ !-<W10!VO\ PL_6_P#G
MUT__ +]O_P#%ULZ;\4+>66./4K%H%*@--$^\;N,G;C(7J>I/UKS&B@#Z,CD2
M:))8G5XW4,K*<A@>A![BG5SG@+_D2]/_ .VG_HQJZ.D 4444 %%%% !1110
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MC?R+L8!MY6&XG&3M_O#@^_'(%(#?HHHH *^<:^CJ^<: "BBBF 4444 %>U^
MO^1+T_\ [:?^C&KQ2O:_ 7_(EZ?_ -M/_1C4 ='1112 **** "BBB@ HHHH
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MX\GU3S]/TT^58-\K2X(>4=_HI].I YZD5Q5%%, HHHH **** "BBB@ HHHH
M**** "BBB@ IT<CPRI+$[)(C!E93@J1T(/8TVB@#T?PI\0?]1IVLM_LK>LWY
M!_U^;/IGN:]%CD2:))8G5XW4,K*<A@>A![BOG.NO\&^,GT.5;*]9GTUVX/4P
M$]QZKZC\1SD% >OU\XU]#V=Y;W]I%=6LJRP2KN1UZ$?T/MVKYXH ****8!11
M10 5[7X"_P"1+T__ +:?^C&KQ2O:_ 7_ ")>G_\ ;3_T8U '1T444@"BBB@
MHHHH **** "BBB@ HHHH **** /G&BBBF 4444 %%%% 'H_PI_YB_P#VQ_\
M9Z]'KSCX4_\ ,7_[8_\ L]>CT@"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ^<:***8!1110 4444 >U^ O^1+T_P#[:?\
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M110 4444 >U^ O\ D2]/_P"VG_HQJZ.N<\!?\B7I_P#VT_\ 1C5T=( HHHH
M**** ,?Q7?OIOA?4+J+=Y@CV*5;:5+$*&!]1NS^%>$UZS\3KCR_#L$*S;6EN
M5S&&P74*Q/'< [?QQ7DU, HHHH **** '1QO-*D42,\CL%55&2Q/0 =S7O\
MI&FQ:/I-MI\)RL*8+<_,W5FP2<9))QVS7DWP_L?MOBV!RL;);(TS!QGH-HQ[
MAF4_A7LU( HHHH **** "BBB@ HHHH **** "J&N::-7T2\L"%+31D)N) #C
ME2<<X# &K]% 'SC16[XRM4L_%^I11EBK2"4[CSEU#G\,L:PJ8!1110 4444
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MKF? $B/X,LE1U9D:17 .2IWL<'T."#^(KIJ0!1110 4444 ?.-%%%, HHHH
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MBBB@ HHHH \#\0_\C+JO_7Y-_P"AFLVM+Q#_ ,C+JO\ U^3?^AFLVF 4444
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MTP"BBB@ HHHH ]9^&'_(M7/_ %^-_P"@)7:UQ7PP_P"1:N?^OQO_ $!*[6D
M4444 %%%% 'SC1113 **** "BBB@#VOP%_R)>G_]M/\ T8U='7.> O\ D2]/
M_P"VG_HQJZ.D 4444 %%%% !1110 4444 %%%% !1110 4444 <G\1K3[3X2
MDEW[?LTR2XQG=D[,>WW\_A7CM>U^/?\ D2]0_P"V?_HQ:\4I@%%%% !1110
M5]'5\XU]'4@"BBB@ HHHH XCXH2(/#]K$742-=!E7/) 1LD#T&1^8KRBO1_B
MM_S"/^VW_LE><4P"BBB@ HHHH *]_P!"C>'P_IL4J,DB6L2LK#!4A!D$=C7@
M%?1U( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG&OHZOG&@
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MZI-?7#-EV.Q"V1&F>%'3@?3GD]34WB#Q!=^(M0-Q<'9&N1#"#E8U_J3W/?Z
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M&P#A@<@X/O7T57SC7T+I]W]OTRUO-FS[1"DNS.=NX XSWZT@+-%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5\XU]'5\XT %%%%, HHHH *]K\!?
M\B7I_P#VT_\ 1C5XI7M?@+_D2]/_ .VG_HQJ .CHHHI %%%% !1110 4444
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M#\'W]:\DKVCP!(C^#+)4=69&D5P#DJ=['!]#@@_B* .FHHHI %%%% !1110
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M\XT444P"BBB@ HHHH ]'^%/_ #%_^V/_ +/7H]><?"G_ )B__;'_ -GKT>D
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M-P99E8XE8?PCU4'G/<@8Z9(!R6LW$5WKFH7$#;HI;F1T;!&5+$@X/M5*BBF
M4444 %%%% 'K/PP_Y%JY_P"OQO\ T!*[6N*^&'_(M7/_ %^-_P"@)7:T@"BB
MB@ HHHH ^<:***8!1110 4444 >U^ O^1+T__MI_Z,:NCKG/ 7_(EZ?_ -M/
M_1C5T=( HHHH **** "BBB@ HHHH **** "BBB@ HHHH YSQ[_R)>H?]L_\
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MBUXI7M?CW_D2]0_[9_\ HQ:\4I@%%%% !1110 5]'5\XU]'4@"BBB@ HHHH
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M%% !1110 4444 %%%% !7M?@+_D2]/\ ^VG_ *,:O%*]K\!?\B7I_P#VT_\
M1C4 ='1112 **** "BBB@ HHHH **** "BBB@ HHHH ^<:***8!1110 4444
M :6DZ]J>A^=_9USY/G;?,_=JV<9Q]X'U-:7_  GOB7_H)?\ D"/_ .)KFZ*
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M7!FF(RL:_P!2>P[_ $!([;QUI-IHO@JSLK*/9$MXI)/+.VQ\LQ[D_P#UN@H
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M -_'_P#B*ANOAOK]O$'B%K<L6QLBEP0/7Y@HQ^/>@#D**Z3_ (0+Q+_T#?\
MR/'_ /%4?\(%XE_Z!O\ Y'C_ /BJ .;HK6N/"^NVT[0R:3>%EQDQQ&1>F>&7
M(/YUDT %%%% !1110 4444 %:WA_Q!=^'=0%Q;G?&V!-"3A9%_H1V/;Z$@Y-
M% 'T'IFI6^KZ;!?VI8PS+E=PP00<$'W!!%6Z\B^'WB!M,U8:=,<VMZX49)^2
M3HI 'J< _@<\5Z[2 **** .%^(/A?[=;'5[-(UN+="UP.AD0#KGIE0#[D=^
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M $!]0_\  9_\* ,VBM+_ (1[6_\ H#ZA_P" S_X4?\(]K?\ T!]0_P# 9_\
M"@#-HK2_X1[6_P#H#ZA_X#/_ (4?\(]K?_0'U#_P&?\ PH S:*TO^$>UO_H#
MZA_X#/\ X4?\(]K?_0'U#_P&?_"@#-HK2_X1[6_^@/J'_@,_^%'_  CVM_\
M0'U#_P !G_PH S:*TO\ A'M;_P"@/J'_ (#/_A1_PCVM_P#0'U#_ ,!G_P *
M ,VBM+_A'M;_ .@/J'_@,_\ A1_PCVM_] ?4/_ 9_P#"@#-HK2_X1[6_^@/J
M'_@,_P#A1_PCVM_] ?4/_ 9_\* ,VBM+_A'M;_Z ^H?^ S_X4?\ "/:W_P!
M?4/_  &?_"@#-HK2_P"$>UO_ * ^H?\ @,_^%'_"/:W_ - ?4/\ P&?_  H
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MZQ (=0M(YU'W2PPR\@\,.1T'0\T ?/U%>@:M\,+B-FDTFZ66,*3Y5P=KY '
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MNCK-T#2_[&T*TT\MN:)/G.<@L26;' XR3CVK2I %%%% !1110 4444 %%%%
M!1110 4444 %%%% '.>/?^1+U#_MG_Z,6O%*]Z\1Z4^M:!=Z?%(L<DJC:S#(
MR&# 'V.,9_G7BNI:'J>D,1?V,T*A@N\KE"2,X##@G'H>QI@9]%%% !1110 5
M]'5X[X3\'ZAJ6H6MY<6WE:>CK(S3IQ*!@[0IZA@>O3&>O2O8J0!1110 4444
M %%%% !1110 4444 >?^)?AREPSW>B%8Y68L]LYPAXZ)QP<]CQSU &*\UN+>
M>TG:&XADAE7&Z.12K#(SR#[5]%5FZSH6GZ];""_AW[,F.13AHR1C(/\ 0Y'
MR#B@#P.BNZU;X9ZA;O))ID\=U%U6.0[).O3^Z<#'.1GGBN,NK.ZL91%=VTUO
M(5W!98RA(]<'MP:8$%%%% !1110 4444 %%%% !16IIOAS6-64/9:?-)&5+"
M0C8A .#AFP"<]L^OI7>:+\,[:#$NL3_:7_YXPDJ@Z]6X8]CQC!'>@#S_ $G1
M;_6[M;>Q@9SN >0@[(P<\L>PX/UQQDUZIX:\#V&B*EQ<A;J_V@EW *1L#GY
M1P>G)YXXQDBNFM[>"T@6&WACAB7.V.-0JC)SP![U)2 **** "N*^)_\ R+5M
M_P!?B_\ H#UVM8_B?0QX@T26R#*DP820NV<*X]<=B"1WQG.#B@#PFBK=_I=_
MI<OEWUI-;L6*J9$(#$==IZ$=.1ZU4I@%%%% !7M?@+_D2]/_ .VG_HQJ\ATW
M2-0UB<PZ?:23L/O%1A5X)Y8\#H>IYKV_0-+_ +&T*TT\MN:)/G.<@L26;' X
MR3CVH TJ***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !5:[T^RO]GVRSM[C9G9YT2OMSUQD<=!5FB@#-_X1[1?^@/I__@,G^%'_
M  CVB_\ 0'T__P !D_PK2HH I6^C:7:3K-;Z;9PRKG;)' JL,C'! ]*NT44
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M+2A9!CTP O/3G-=Y10!YI<?"N=8&-OJT<DO&U9("BGGN03CCVJC_ ,*PUO\
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M444 4)-"TB:5Y9=*L7D=BS,UNA+$]23CDTS_ (1[1?\ H#Z?_P" R?X5I44
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M*L4D1@RLMN@*D="#C@U?HH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .#^*5TB:
M18VA#>9+.95..,*I!S[_ #C]:\MKT#XIW2/?:=: -YD4;RL<<88@#'O\A_2O
M/Z8!1110 4444 =9\.;3[3XMCEW[?LT+RXQG=D;,>WW\_A7L5>6_"V!&U>^G
M,RB1( BQ=V#,"6'/0;0/^!#\?4J0!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %><?%;_F$?]MO_9*]'KROXGWWG:S:62M&RV\)<[3E@SGD'\%4
M_C[T <+1113 **** "ND\!?\CII__;3_ -%M7-UU7P[M7N/%\$J%0MO')*^3
MR05V<>^7'ZT >R4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#R;XG_\ (RVW_7FO_H;UQ5>C_%;_ )A'_;;_ -DKSBF 4444 %%%% '8
M_#2XBA\4O'(V&FMG2,8/+95L?DI/X5Z[7SUI]]/IFH07MNV)87#KR<'V..Q'
M!]C7OFGWT&IZ?!>V[9BF0.O(R/8X[@\'W%("S1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 -DD2&)Y975(T4LS,<!0.I)["O ]<U(ZOK=Y?DL5FD
M)3< "$'"@XXR% %=S\0/%B>4^BZ?,WF;L74B'@#O'GN?7'ICG) \VI@%%%%
M!1110 5Z/\++#_D(:B\7]V".3=_P)QC/^YSCZ=Z\XKW/PEIG]D^&;*W9-LK)
MYLN8]C;FYPP]0"%Y_N_A0!MT444@"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YU\
M2O#Y=4URW1<(HCNN0#C("MTY/.#S_=XP#7HM-DC2:)XI45XW4JRL,A@>H([B
M@#YSHKK_ !EX-?0Y6O;)6?37;D=3 3V/JOH?P/.">0I@%%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH5548"@= !V%.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>lgnd-20201030_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lgnd-20201030.xsd" xlink:type="simple"/>
    <context id="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2020-10-30</startDate>
            <endDate>2020-10-30</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV80L2ZyYWc6MjE0MTc4NmQ5NTU3NGNmZjhjMGI0MGI0M2ZkNmU0MjAvdGFibGU6NWVjNmQwMTYxMTliNDEwZDkxYTM2M2QxMTk2YzVkZWEvdGFibGVyYW5nZTo1ZWM2ZDAxNjExOWI0MTBkOTFhMzYzZDExOTZjNWRlYV8yLTEtMS0xLTA_0ae55155-b815-484d-8d94-ca293c69179e">0000886163</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV80L2ZyYWc6MjE0MTc4NmQ5NTU3NGNmZjhjMGI0MGI0M2ZkNmU0MjAvdGFibGU6NWVjNmQwMTYxMTliNDEwZDkxYTM2M2QxMTk2YzVkZWEvdGFibGVyYW5nZTo1ZWM2ZDAxNjExOWI0MTBkOTFhMzYzZDExOTZjNWRlYV8zLTEtMS0xLTA_06a9caea-9156-4e7a-ae6d-905c3271aa15">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF85Nw_1ce5cf2c-3c70-413c-a1ee-92f2160c4487">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF8yNTI_24a11774-bb8f-485c-a8b7-62092810aa8f">2020-10-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF8yNTY_ad6c1bba-57d5-4a6d-8553-e957e3fa3156">LIGAND PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6NDIxYjY2OThlMTRjNDZiYmI1ZDA3MjYyZGQxZGYxZGQvdGFibGVyYW5nZTo0MjFiNjY5OGUxNGM0NmJiYjVkMDcyNjJkZDFkZjFkZF8wLTAtMS0xLTA_2fcffdfd-211e-4d46-920f-effcaa9bc47e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6NDIxYjY2OThlMTRjNDZiYmI1ZDA3MjYyZGQxZGYxZGQvdGFibGVyYW5nZTo0MjFiNjY5OGUxNGM0NmJiYjVkMDcyNjJkZDFkZjFkZF8wLTEtMS0xLTA_0a7a8761-51d4-4e7d-89a0-2989ce674eb9">001-33093</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6NDIxYjY2OThlMTRjNDZiYmI1ZDA3MjYyZGQxZGYxZGQvdGFibGVyYW5nZTo0MjFiNjY5OGUxNGM0NmJiYjVkMDcyNjJkZDFkZjFkZF8wLTItMS0xLTA_a99a64cc-e76c-4cd8-bc6c-3043be26da8e">77-0160744</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6ZWQzNjYyNWQ1NmQ3NDQyNmI5NGVmNTg0MTA4ZWY1NDUvdGFibGVyYW5nZTplZDM2NjI1ZDU2ZDc0NDI2Yjk0ZWY1ODQxMDhlZjU0NV8wLTAtMS0xLTA_586e777e-1bad-414a-b12a-57a180b72279">3911 Sorrento Valley Boulevard, Suite 110</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6ZWQzNjYyNWQ1NmQ3NDQyNmI5NGVmNTg0MTA4ZWY1NDUvdGFibGVyYW5nZTplZDM2NjI1ZDU2ZDc0NDI2Yjk0ZWY1ODQxMDhlZjU0NV8xLTAtMS0xLTA_ce68e441-0689-452f-b102-de8653963307">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6ZWQzNjYyNWQ1NmQ3NDQyNmI5NGVmNTg0MTA4ZWY1NDUvdGFibGVyYW5nZTplZDM2NjI1ZDU2ZDc0NDI2Yjk0ZWY1ODQxMDhlZjU0NV8yLTAtMS0xLTA_921cf68e-1f78-47ac-9b80-f88596a63822">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6ZWQzNjYyNWQ1NmQ3NDQyNmI5NGVmNTg0MTA4ZWY1NDUvdGFibGVyYW5nZTplZDM2NjI1ZDU2ZDc0NDI2Yjk0ZWY1ODQxMDhlZjU0NV8yLTItMS0xLTA_62bfa62e-9177-4fb8-a16c-1885fe12cc33">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF8zMzQ_8423a1c8-95b7-448e-9fdd-38376299b632">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF8zMzg_05a2ae96-5e3e-4016-86f1-b7201f7bfd66">550-7500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF82MzU_a2af5cb6-6e56-45f0-a917-e9a3b9b373af">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF83MjQ_0db458eb-8250-4b05-813c-6b2fb298eb61">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF84MTQ_910c9bc4-7b7a-4e4a-9da6-c7c9b3aa050b">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF85MjA_99592698-f060-4958-ae1b-326f12d87e7b">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6ZGI5MTc2MmQ0ZjBmNGM5Zjg2OTQ1MTI0ZWY2N2Q2ZGMvdGFibGVyYW5nZTpkYjkxNzYyZDRmMGY0YzlmODY5NDUxMjRlZjY3ZDZkY18xLTAtMS0xLTA_7028af25-f3ca-49e7-9177-e41af13512e3">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6ZGI5MTc2MmQ0ZjBmNGM5Zjg2OTQ1MTI0ZWY2N2Q2ZGMvdGFibGVyYW5nZTpkYjkxNzYyZDRmMGY0YzlmODY5NDUxMjRlZjY3ZDZkY18xLTEtMS0xLTA_df6977e7-9d26-4c77-b323-d7748b25d850">LGND</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGFibGU6ZGI5MTc2MmQ0ZjBmNGM5Zjg2OTQ1MTI0ZWY2N2Q2ZGMvdGFibGVyYW5nZTpkYjkxNzYyZDRmMGY0YzlmODY5NDUxMjRlZjY3ZDZkY18xLTItMS0xLTA_9e64cb86-1250-4668-925a-6932559fba61">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030"
      id="id3VybDovL2RvY3MudjEvZG9jOjEyNWRmN2FhZTU0YjRkY2U4NjUyMzlhNTE1MTk2YmE5L3NlYzoxMjVkZjdhYWU1NGI0ZGNlODY1MjM5YTUxNTE5NmJhOV8xL2ZyYWc6ZTE5MDc2YzVkZDU3NGM4YWE2NTBhNDlhNjU3ZDk3MjQvdGV4dHJlZ2lvbjplMTkwNzZjNWRkNTc0YzhhYTY1MGE0OWE2NTdkOTcyNF8xMzU0_3e5516f7-906e-4e59-8c25-340a31dd95e3">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140664032095800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Oct. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000886163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 30,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIGAND PHARMACEUTICALS INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0160744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3911 Sorrento Valley Boulevard, Suite 110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">550-7500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LGND<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MOKZ&A@\2SULRIWO\&6HQJ#=;U6-8EZ5JCS^%]RBYGQON_Q+%#U!+ P04
M" !N0%Y1EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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MOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ ;D!>40=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !N
M0%Y1,O"4K^T    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " !N0%Y1F5R<(Q &  "<)P  $P
M@ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &Y 7E'1*AI+
M3@0  %(0   8              " @0P(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " !N0%Y1@ZFE ]0!   R!@  #0
M@ &0#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( &Y 7E&7BKL<P    !,"
M   +              "  8\.  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( &Y
M7E$9117U-P$  "<"   /              "  7@/  !X;"]W;W)K8F]O:RYX
M;6Q02P$"% ,4    " !N0%Y1)!Z;HJT   #X 0  &@              @ '<
M$   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !N0%Y1
M99!YDAD!  #/ P  $P              @ '!$0  6T-O;G1E;G1?5'EP97-=
:+GAM;%!+!08     "0 ) #X"   +$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lgnd-20201030.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lgnd-20201030.htm">lgnd-20201030.htm</File>
    <File>lgnd-20201030.xsd</File>
    <File>lgnd-20201030_cal.xml</File>
    <File>lgnd-20201030_def.xml</File>
    <File>lgnd-20201030_lab.xml</File>
    <File>lgnd-20201030_pre.xml</File>
    <File>q32020earningsreleasee.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lgnd-20201030.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "lgnd-20201030_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lgnd-20201030_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lgnd-20201030.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lgnd-20201030_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lgnd-20201030_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lgnd-20201030.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "lgnd",
   "nsuri": "http://www.ligand.com/20201030",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201030.htm",
      "contextRef": "i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.ligand.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201030.htm",
      "contextRef": "i917ee7342e1a4e9086a9bc0db9952f51_D20201030-20201030",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0000886163-20-000112-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000886163-20-000112-xbrl.zip
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MR=2IY;B2YUB61GQ-/JM-0;F!J80B.N!#LZ!:CP"^R2Y,)Z%A(_+8^$\V*:'
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M%-0'IZY<#D_I#=$4M8;,Y5ZWAX((-;(4[?; >6;)IQ59=YFFR:@3LFD3)T[
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ME"@W;VYCN@(=CM*1TX?Q\E5G* RH$X1@Y>9#TPRE.32;,)&DF%(P.Z-@EAG
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M!^Y<?@'<.Q9>C1ONIX.PSMC7L3MDO>$IN_U^=!);P_:07XQ^ %!+ P04
M" !N0%Y1FGK^MH,!  #. @  %0   &QG;F0M,C R,#$P,S!?8V%L+GAM;)V2
MWV_;(!#'W_-7,/:Z,]A.&L>*4ZFI)DW*I"I;U;YBP#:*#1'0VOWO%UA_J&NK
M2GL!W=WG[GMWL#Z?AA[=2^N4T15.$XJ1U-P(I=L*7__^#@4^W\QFZR\ MQ?[
M';HT_&Z0VJ.ME<Q+@4;E.W0CI#N@QIH!W1A[4/<,8!.3MN;X8%7;>931C/X;
MM>4BIW/1Y!RR):4PSRB#XBQGP!>+NEB>%76:-M_:LF%YP[)<PI(7 N:,%E O
M> &K@K-L+NE2B"86[94^E.&HF9/H-)QVT:QPY_VQ)&0<QV2J;9\8VY*,TIP\
MT?@1G][P8Q[I=+5:D1A]1IUZ#SR53<GMS]TOWLF!@=+.,\V#@%.EB\Z=X<S'
MG7_:%_J0"!8\81!<D&:0I\GD!-[,$/J[#FMZN9<-"O?U_L<KR5ZU3(N$FX&$
M,-F:TV>X8FUH-B;[AZ.LL%/#L7_V=58V%>Y;+2"\:DIS&B2_OB23%W7.>G[7
MQV%W)_NQ1!#[GT;DY*464@2%-7GUVIO9'U!+ P04    " !N0%Y1\,Z7E0H"
M  !W!@  %0   &QG;F0M,C R,#$P,S!?9&5F+GAM;*V476_:,!2&[_D57G8[
M8R<A'R"@TI@F36+2Q%:U=Y-CGR06B8T<4^B_7^("A=*JTIJ;R,?G/>]Y;$=G
M>K.O*_0 II%:S3Q_2#T$BFLA53'S;O]\QZEW,Q\,II\POO^Z6J)OFF]K4!8M
M## + NVD+=&=@&:-<J-K=*?-6CXPC.>N:*$WCT86I44!#>C+K)E$(1V)/.0X
M2"C%HX RG,8APSR*LC2)T\SW\R_%)&=ASH(0<,)3@4>,ICB+>(K'*6?!"&@B
M1.Y,*ZG6D^Z3L090>SC5N'#FE=9N)H3L=KOA/C/54)N"!)2&Y*CV#O+]E7X7
M.K4_'H^)RYZDC7Q-V-KZY/[G\C<OH698JL8RQ9\;M.V%/16>TT3D*=E*&SEI
M7/U2<V;=\[Q[!/2FHHOP48:[+>P'./2'^T9X\P%"3S?'##>Z@A7DZ+"\7?VX
M)I7*$B%K<M 05E4ML7.PCQN8>8VL-Q4<]TH#^9OTQR-W4%&'\[ES(Q]F*EL0
MP[<9X'875/>#]\CXFOO'F4]>6$#.MI7MD?C:NU=>73/9YP5?6?= ZXQP#74&
MID_4"]\SSB/D2\+.LI(%4V+(=4T<W$*W4_@7*^!]L*I0 G?CU*<A=03/Q6?=
MVV>62G:38]F&!X>NU_]PP-Z"$B \),7,D^W0C44<QC[C8B12FOJ4!33/8IK'
MD(SA[P71E%R,Y?G@'U!+ P04    " !N0%Y1HF3X1X8*  #.7@  %0   &QG
M;F0M,C R,#$P,S!?;&%B+GAM;,U<;6^;2A;^WE_!YG[9E3KQ  /,5&VNNKGM
MJMK<MFI3]6I7*VM>'50,$29-\N]W!MN)L<%FP*;T@TOLPYGG/.8Y9XX9YO7O
M#_/$^2GS19RE;\[<<WCFR)1G(DYG;\Z^7;\'^.SWBQ<O7O\-@+_^^>7*^2/C
M=W.9%LYE+FDAA7,?%S?.=R$7/QR59W/G>Y;_B']2 "[*DRZSV\<\GMT4C@<]
MN/UI_BKP(1+*Y\"+( 3(@Q3@T*> !P'#48B9ZZJ7LU>*^HIZO@01QP(@"C%@
M <> 8$X])&$DA"J=)G'ZXY5Y870A'1U<NBC_?'-V4Q2WKR:3^_O[\P>6)^=9
M/IMX$/J3M?79ROQAQ_[>+ZU=0LBD_/3)=!'7&6JW[N2O/Z^^\ALYIR!.%P5-
MN1E@$;]:E&]>99P6)><'<3F-%N8OL#8#YBW@>L!WSQ\6XNSBA>,LZ<BS1'Z1
MRC'_?_ORH7%(,C$6DU3.S#?[6>9Q)KX6-"^N*).)1E]Z*QYOY9NS13R_3>3Z
MO9M<JGJW29Y7O!J4Q*!T0X/RMZ;!)CW@'PEOL8OU".#*<#\>"^,^3C\>#>ZU
MS@_R]( WAND->7E!O4O%4-?NTU"]H9\>\;$NBZR@R0"7Q?,P&Y 3\\:5/EH-
M8QSM2:;E.*O4O0%5/A0R%7*9+2NNG5B\.=-'4R'CZ?<\+K3A93:?WZ7Q,G,O
MIBQ4W ]U40J]4-<NKAC !"/@"T*H3XD0PIT63Q?U5*;@V]?U^.4@!T8XLXBM
M:-!H+A?97<Z?J]L\J2M9NEJ9^H8G*9W+Q2U=G:!AFHG $OG%"J131?EZ\AQ0
M%QJ3TY.3C(J7C%>0)&8JD.7;L6?\<.S/VEIHV&7@"\G/9]G/B3Y7$^ 2<P#,
M 8#N:FKP6[/?R<X7^#9?HZ4Y/\#URF+",SW;N2U A78S.VP95I&U_.Z7!.IA
MSYPL%S+7,]B:$"K7X.=<&E]ZDBO-//;:R#__I)3,I]Q'(59< .S[ 4!*ST5I
M%.B,%"D$/8]"_=)6S\W#C$W4&BG@&U"=)5:G!-M>VWMX/2SPX[!U8I5W(\I*
M[(=YZ*'X/<X'D_WA #>UW\+:/@&\2XNX>/R@F]S\-LO+?*+[CD*/=)<6^>-E
M)N148 Y#C!1@TG<!(C("%'D4R% 03A#$/L9M,T&+\<:6$I:0G0KFETZ)6M/L
MK) [!GK[!-&&]\.9XLALGCAE'(-(JP1B04^/3-)FE,%2BD7(F[G%YK2N2>:M
M$/IJ6ESJPT_Y=7:?3EFDA*^@#P).0IU8A \(C1 (H.+05\+%?NLI1L,8(TTF
M*YPO'8/47/P&JVWVV"6T;<;H1=,P6<*.H0YIH9&#WJE@U_/ \F\,;5?RS:;V
M,O^:)3&/BSB=_:E31Q[39*J;_RCT?0P@0@@@%'H !Q$$H8>X9*Z"RH_:*GS7
M_=C$_8S064-LK^D:]@[+N1\G)U:R#1U6 FZ.NH=V:YP.)MOF@#85N\>J9TU>
M_7<5I]*=^M#CPH422$BQKLH>!E2Y"A#751'7'W+..E7ES5'&)MWMJK,Z< Q8
MYU-J/;.O(]:R.G>E:^#ZW)JI[C6ZCHEC5>F*[U]3I^O":ZS4M<8=:K7D=[GV
M^NZ!W^AO5W[4W_B4DB#$RO= A#@'B&OY,Q^&0+@HPD2AB,O6\_&Z <8F^C5&
M9PW2,2@M2G8=B2V*=D]J3EVV[5BQJ]Q[0N]3N^O<#E>]]P15J=_[[.PE;.;L
M;W-)R]^*5 1]0C$! 9,10#ZG@(:1GG<'^E^(A AET%:ZFX[')MFR&S3@+']O
MJY!U6*)=*3BQ-%M&;R7)NE![2+'B;C )U@6Q*;W:SSM(+OLI\[=L4>24%U/"
M%(DBY@+E1L0TMV89%E% ,*A[7H^S2-+6FMOT/#K1&7#.+9W)<PO%5;AJ(;FN
M#)Q:<V7P_UTC^]^15%<7;1_95?P-I[NZ,"K"JS7HVJY>TX</0NI#M;KW_?%N
MSF0^]6 42)\2( +=K2*.74 "R4 @/1EQ%GB<$+N6M6&DL2ESU8QIM$X5KK/$
M:]NV-A'<MG4] FW#M*_VC'5H7P^PT;N%;?(_<!M[(,S=5O;0"5W3P_LXD:L+
MEE-74(8YP,)C +D, 0H%!V'@>[Z*E.YR?;N,\.Q\I$G  .PH^PWBVBJ]&QW#
MB+L-$QWDO!MR;P5ON!Q8M+O![.JTQL9>FNMG)*[UJ5,4X!!2Q4%$N-"%V@L!
MAH$'N(M=0:!DBK9N4S<=CTV23P^&&'#MU5CAZK 2NS)P8A6V"]Y*@'61]A!?
MQ=U@PJL+8E-TM9]WK867VE%.DP^ID __EH]3ZKO$HUAHO7$%D!\RP+06 8TP
M(2X-*8Z474'<&F%L$ES5@A5*IX3I:)RVM7&;R+8%L@<]PU3)]LQTJ)4-T?<N
MF-M^!ZZ:#6'MELXFPZYR?C>7^2Q.9__*L_OBYC*;W]+T<<H1"Q65!/!0F@<!
M70PPAA+XE 4H9 PATGIYQ9YQ1BKM-59G"=99H;45>#VU;67>F[!AQ&[+50?)
M[V6BM_#KO0\L_[TA[B:!_>;=;]JZ'KN.BT1.!>60F(<R1!1*@ )" 48>!P$D
M 80>(HAPVQNV:^=C$WT)RLF4XWI_9_]PUG#M[]8^L7=8XGTX.;&N;>GH=)MV
M.^XCW*)]<CGX[=GM8.INS>[8V(O4/,N>?+[)TO4O*I"Z>H[M"4 #J6?>GA\!
M)I$ T@\$QSY"OMM:I-O.QR;2$I]3 K3^*6J'N,/Z[$/'B?5IP825-)M"[B'-
M'9>#2;,IF$UI-MKT7/-8/M_P*?^<9S]C#70J6$@%"7T@F&_NYD)BECU20*F/
M(B$A1@)V6O:X-=#8)+N]GN_I>9PUX(Y+'[?Y;3NA[L_:,#/J#H1U7P'9P,:Q
M%D%NN_\UZR ;@FQ<"MED;Y\8WLYE*LQ/;^\3.IL2R4/F45VF%:8 F055.&(0
M"!6ZBG**H=<Z$U0\CTWZ3^ <@ZZ]SJMT'19V9Q).K.26\5O)MC;6'CJM^AM,
MF+5A;"JQWJ!G3?Z<+0J:_">^+9?I81(1Y>F)LPKT"Q(<Z>Y6*!"X 1-!Y 5$
MM=Y1I'F8L8ERN[PLP3H:;:='C&N9M:S%G?D:N!*WI:I[':YEXEA5N.K\U]3@
MV@ ;*W"]M7T2N,ZIV6/OZ^.<9<D4*24]@3G@F$" H"" A3H#8 21GHPS2;W6
M#7/%\]BDO@+G+-&U5W:5KL-B[DS"J7_#:A>_E5QK8^VAT*J_P419&\:F#NL-
M>N\ ]&&QN)/YYGXU(>(RH"P$'M?D(!5 0%VD7X3'8*B0ZP:MUU8>&FQL MW9
MY&:)^#B; NU2?5C)QR3PQ.+NQ5V??8(:23G>;D&[0_RJ/8,:@]VS<U#S.=U7
M=SUM^_B'[LFGE'D1<14"810$ "$I  LP R+@1"$58NZV[J!K1QA;HGA:\K1$
MZ6B8CL%IO_2K2N3AC-";GA.G 6MF.JT+JXW^" O$JGX'7RE6&U;=DK%ZPZ[=
M^!<YB\T3&VE1/M$:08@A4AA Y2* , H!BT(%PI"Z#** !\ARFY[J &,3\ZJM
M? 9I^5AP+8EM6^[NU S3;+=EI4./71]Z[^YZR^W ?75]4+L==8-=DX0W>;_2
M1Q<OUN_$RPW0+U[\'U!+ P04    " !N0%Y1L=F@KZX&  !N,0  %0   &QG
M;F0M,C R,#$P,S!?<')E+GAM;-6:6T_<R!+'W_D4<V9?3S'=[;ZBP(K#)D=H
MV0U*6&6U+Z/JVV#%8R./"?#M3[>!328D.=9@">_+7.RVJ_I?/U57E_WJY]MU
M-?L4VDW9U(=SND_FLU"[QI?UZG#^Q\4;T/.?C_;V7OT+X,__O#N;_=*XZW6H
MN]E)&[ +?G93=I>S#SYL/LYBVZQG'YKV8_D) 8[ZBTZ:J[NV7%UV,T88^?IL
M>R *PGTL'#!%"'!&$+0L$)P05BNI+:7QWZN#B$5$5@103GO@2#18X308[9#Q
M0)3WL;]I5=8?#_*'Q4V8I<G5F_[OX?RRZZX.%HN;FYO]6]M6^TV[6C!"BL7C
MZ/G#\-LGXV^*?C0UQBSZLW\/W93?&IAN2Q=__G;VWEV&-4)9;SJL73:P*0\V
M_<&SQF'7:_Y__9I]=T3^!X_#(!\"RJ"@^[<;/S_:F\WNY6B;*KP+<9:__WAW
MNF6R*E=8^WW7K!?Y].*D23"<XRH[VU_<W5V%P_FF7%]5?Q^[;$,\G%>KVD..
M*B4%R29_^GSQXK/UJS9L$C#];,_2@8=[9&N[>!)NNU#[<#^_1QM5X[8&55G=
MIGV\LD(;JO[HTH=RV=_YV&ZZ%EVWU(JP(JHT%6$"<$]%HDH9"(G+J#@*Y]GV
MQ+/3F^1U'XQ-</NKYM,BW3@%A9K\ _(/(/0A%#\],7JOSV[>OZZ[LKL[29*V
M6)TF*6Y_#7=+[0O!@Y<@)%K@UD9 -!&BM4292+F*:H19?-/X]FR^C/=QZV9-
MZT.;4LNC=6S=D]AO8_TP8G&%;;H1N,NR\H]7YQPS1B2[9DQ%[^.6_)[/TO1C
M:-O@S^[#]MU9]E/L4N8-_<CG('&<,K+/6?E-A:NEE-)J2E3.E2RE5(U@/'*@
MRB$J1H62;@04MHP.0H!-%X'=%7SAT#^NQQ=I[))P6FA)"_"6)62YY8 R+94D
M:&?1V_0Y1N2_M#DH\,5T [^S?A.)^WEHR\:_KOTOJ1I;QE0M\5@P\-$9X-13
ML 73()%)),XY@WY$ +:,#R*!3Y^$W15]823NE[%W855F)>KN=UR'9> Z*F9)
M0CK7UYY[0,)2D2T(DQR=P\*.5A=LVQX$A)@N$,_6<Q(\G*;=7'O5M+WP[Y/^
MX:2Y3I7.W4GCP](7+A+K.01#<I$C(EB35/+2I/J&1A9D,1H>/W1E$"URZK2,
MI_8DX'E35N'WZ[4-[1)5**A.:Z-BBD(JC!E8%RT40F!A@D"GXFBD?+8[" LU
M=2QVU'$2#%S@[:E/6I6QO&]9/$RD0$^E(QY$U 7P* 1@M A!6FFM*_0XM<8/
MG1A$AYXZ'6,H/ E4CKU/(=@\?)V5=:!+QX6(-GJ0K/ IYQD+FFN5%DP=@B2%
M#GZ\O/$-!P8A8J:.R'.5G1(>)^GGV_:BN:F7WF@7T\S!*2'31EMH0,TC"",$
M-9H0BF%L.#Z;']:W(O\0-G:4=4ID] 73V_:\;3Z5M<O[\50>^:2+%S3-(]$.
M.O?_D1 F:!(+#1T;CZ]\&,;(Y)N;(P@\)5#.FTV'U5_E55]6\X2T9$2#1LF!
M*Z1@C L0->?1\6C3<CDV)EL>#(-DPNW/D<1]841R!CQN _9^(Z%2$&= 2X/
M-3HP@3F0VJ9<R#4CH^2.+VT.PV#"S="=!7SAP.>'J=7Y95,_;K)B%-H1RT Y
ME7PW*;DAEQY4*HHHX2I(KD<(_M=VAP$PX1[HLX1\80@^M&77A?JD6:^OZX>-
MU&9)@J-.HTD%4&'RBP,%(.;.'5J/2M@@W!@5YC>-#\-APAW0YTOZPDR\;ZK2
ME5U9KWY+A4];8K6,4A+F)4ON8MHU*>U %TZG_5-BV7J)BID1@'AJ>1@-$^YP
M/E/,%T;AO V9XY#*WOYY7WZ)I'T;DQ^I"G:Q8,J!]R8_]DN[:6O35 HAK'.!
MAA#'0.+['@Q#8\)=SI'$G18BIYO-=6BWYD*CUYA60\>M !X+"MH&G9GGU(9
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MM7@BY5DZ<+3W<")_Y!?TC_;^!U!+ P04    " !N0%Y1D=C><3Y%  !=00,
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MT(T2W!X"JYY!IN)H+(\3.0'@1\I=/3NTW_DD!%!'(:!W4L*]$FCU'(E<P=(
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M *M J8""1D8^X7!YP/H^THE8N@UKE8N?<0, CH+BEO LRB14PB'S!U(M-JN
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M/J\ L-D4BSELMQ;N:B$Z[QPV6+9N=[H[QASV K(MO=-0@-T$8#MZM]52D-T
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M2P$"% ,4    " !N0%Y1U/&]BXP"  !^"0  $0              @ 'X%
M;&=N9"TR,#(P,3 S,"YX<V102P$"% ,4    " !N0%Y1FGK^MH,!  #. @
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M,#(P,3 S,%]P<F4N>&UL4$L! A0#%     @ ;D!>49'8WG$^10  74$# !H
M             ( !0"T  '$S,C R,&5A<FYI;F=S<F5L96%S964N:'1M4$L%
3!@     '  < T@$  +9R      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
